Outcomes

The current evidence for Cerebrolysin outcomes is limited and mixed, with several important caveats about data quality.

Stroke Recovery
A 2026 systematic review and meta-analysis examining Cerebrolysin as adjunct therapy to mechanical thrombectomy in acute ischemic stroke found evidence from observational studies, though the specific measurable outcomes and effect sizes are not detailed in the available abstracts. One completed Phase 4 trial (NCT01996761) investigated motor recovery effects in subacute stroke patients, but results are not yet published.

Traumatic Brain Injury
A 6-month prospective cohort study of moderate traumatic brain injury patients with nonoperative lesions reported neuroprotective effects of Cerebrolysin, though specific outcome measures, sample sizes, and statistical significance are not provided in the available evidence.

Cellular and Vascular Effects
Laboratory research indicates Cerebrolysin-treated cerebral endothelial cells release exosomes that can reverse impaired endothelial cell permeability caused by fibrin or tPA. However, these are in vitro findings that may not translate to clinical outcomes.

Evidence Quality Concerns
The evidence base contains significant limitations:

Multiple retractions of previously published studies on Cerebrolysin's effects in neuropathic pain, Alzheimer's disease, and Parkinson's disease
Limited publication of results from completed clinical trials
Lack of specific outcome data (effect sizes, confidence intervals, p-values) in available abstracts

Other Indications
Clinical trials are investigating Cerebrolysin for Bell's palsy treatment and COVID-19-related anosmia/ageusia, but results are not yet available.

Strength of Evidence: The current evidence is weak due to multiple study retractions, limited published trial results, and lack of detailed outcome data. More robust clinical trial data with clearly defined endpoints is needed to establish Cerebrolysin's therapeutic efficacy.

This information is for educational purposes only and should not replace professional medical advice. Consult healthcare providers for treatment decisions.

Cerebrolysin

Member access required